Long noncoding RNA SNHG4 promotes the malignant progression of hepatocellular carcinoma through the miR ‐211‐5p/ CREB5 axis
Cancer Medicine · 2023-04 · 12 (7) · 8388-8402
DOI: 10.1002/cam4.5559 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 23.12.2022. Verfasst von Jiannan Qiu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, RNA, Long Noncoding, MicroRNAs. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Background and Aims Hepatocellular carcinoma (HCC) is one of the main death‐leading malignant tumors which deserve in‐depth explorations to uncover the underlying molecular mechanisms. Plenty of proofs have revealed that long noncoding RNAs (lncRNAs) participate in malignancy and progression of HCC. Nevertheless, the definite role of lncRNA‐SNHG4 in HCC remains vague.
Methods
To figure out the role of SNHG4 in HCC, the bioinformatics analysis and functional assays and in vivo assay were performed.
Results
Our findings demonstrated that the data from The Cancer Genome Atlas (TCGA) displayed that the higher expression of lncRNA SNHG4 was detected in HCC tissues, which predicted the poor prognosis. The upregulation of SNHG4 was positively associated with worse clinicopathological characteristics. The functional experiments were performed to identify the role of SNHG4 in HCC. We found that SNHG4 enhanced the proliferative, migratory and invasive capacities of HCC cell line, and facilitated the tumor growth in vivo. A series of follow‐up studies have shown that SNHG4 promoted the progression and malignancy of HCC through upregulating CREB5 via sponging miR‐211‐5p.
Conclusion
Collectively, the above findings suggest that SNHG4 promotes HCC malignancy through the SNHG4/miR‐211‐5p/CREB5 axis, providing potential therapeutic targets and prognostic factors for HCC. Highlights SNHG4 is overexpressed in HCC and correlated with the poor clinical characteristics SNHG4 promotes the malignant progression of HCC by reducing miR‐211‐5p expression MiR‐211‐5p inhibits CREB5 expression in HCC The oncogenic effect of SNHG4 in HCC can be reversed by CREB5 silencing
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hepatobiliary Surgery, Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, China.
- Children's Hospital of Nanjing Medical University, Nanjing, China.
- Jinan Microecological Biomedicine Shandong Laboratory, Jinan City, Shandong Province, China.
- State Key Laboratory of Pharmaceutical Biotechnology, National Institute of Healthcare Data Science at Nanjing University, Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, Nanjing Univ…
ORCID-Profile: Jiannan Qiu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
Zitieren
APA
Qiu, J., Wang, P., Chen, Z., Zhou, Y., Zhang, G., Wang, Z., Wu, J., Zhu, Q., & Jiang, C. (2023). Long noncoding RNA SNHG4 promotes the malignant progression of hepatocellular carcinoma through the miR ‐211‐5p/ CREB5 axis. Cancer Medicine, 12(7), 8388-8402. https://doi.org/10.1002/cam4.5559
Vancouver
Qiu J, Wang P, Chen Z, Zhou Y, Zhang G, Wang Z, et al. Long noncoding RNA SNHG4 promotes the malignant progression of hepatocellular carcinoma through the miR ‐211‐5p/ CREB5 axis. Cancer Medicine. 2023;12(7):8388-8402. doi:10.1002/cam4.5559
BibTeX
@article{Qiu2023,
author = {Qiu, Jiannan and Wang, Peng and Chen, Zheng and Zhou, Yan and Zhang, Guang and Wang, Zhongxia and Wu, Junhua and Zhu, Qiang and Jiang, Chunping},
title = {Long noncoding RNA SNHG4 promotes the malignant progression of hepatocellular carcinoma through the miR ‐211‐5p/ CREB5 axis},
journal = {Cancer Medicine},
year = {2023},
volume = {12},
number = {7},
pages = {8388--8402},
doi = {10.1002/cam4.5559}
}
EUVIMED